Daniel Grosslight

CEO confirmed Solaris distribution volume is ramping in Q4 but noted FY2026 impact will not be material. Distribution contracts were not included in original acquisition financial models.

Jason cited two drivers: talented team that listens to customers, and digitized platform that simplifies multi-product onboarding. Not a recent investment but years in making. No significant new spending spike expected, philosophy of consistent elevated investment across businesses. Aaron confirmed BioPharma Services $1B by FY28 target, with Sonexus half of that growth.

Aaron confirmed ION/GIA distribution onboarding is included in current guidance and progressing well. Solaris distribution is NOT yet included in guidance, expected opportunity later this fiscal year but not yet in position to update.

Jason noted CGM Medicare represents less than 15% of total at-Home revenue. Category already seeing low rates vs commercial with only 2 manufacturers. Cardinal positioned as only scaled distributor+provider, emphasizing compliance and operational rigor as competitive advantages.

Jason noted majority of remaining $200-300M will be pricing after operational mitigation. Working collaboratively with customers to avoid supply scarcity of key products.

Jason detailed: North America roughly 50-50 US/Mexico, rest of world very diverse. Has capability to manufacture 50% of Cardinal brand in US but can't resource overnight.

Jason described competitive environment as stable, VA loss was low-margin business with limited Cardinal Brand attachment. Normal customer rotation.

Eva said European distribution again benefited from manufacturer price-increase timing in a developing-market country, but that this would not recur in Q4. World Courier and European 3PL both delivered double-digit OI growth on strong renewals and a stabilizing market.

Bob cited commercial optimization, sales process improvements, and pricing discipline alongside market stabilization. Multiple quarters of OI and volume growth. Jim expressed confidence in full-year international guidance with World Courier, distribution, and 3PL all performing well.

Jim confirmed RCA exceeded expectations driven by organic growth and tuck-in acquisitions. Clinical trial business especially strong. Did not quantify specific accretion vs $0.50 target. Clarified UUG below-the-line items are ongoing.

Jim outlined four capital priorities: internal infrastructure/technology investment, strategic M&A, opportunistic share repurchases, and growing dividend (9% increase announced). OneOncology full ownership is expected and factored into long-term plans.

Jim confirmed the new tax bill is incrementally beneficial. Did not directly address the hospital outpatient rule's impact on MSO competitive dynamics.

Bob clarified that health systems emphasis reflects desire to show broad specialty positioning, not a specific change or new development. Working closely with health system customers on capability and solution sets.

Bob expressed confidence in RCA as market leader and noted it's not surprising to see competitors executing similarly. Emphasized clinical excellence and research network as differentiators.

Britt attributed FY26 outperformance to working capital timing and reiterated three-pillar capital deployment: growth investment, shareholder returns, and investment-grade credit maintenance.

Brian highlighted 50 new programs across 43 unique brands added in the quarter spanning loyalty, hub services, and access programs, not concentrated in any particular area. Britt noted annual verification programs off to a strong start with meaningful volume growth across new programs and customers.

Brian dismissed direct-to-patient pharmacy as small eligible population with limited prior auth impact. Emphasized McKesson has automation tools, last mile delivery, and pharmacy interfaces that can play a role. Committed to working with all governments on access and affordability.

Brian noted HUMIRA and STELARA biosimilar launches slow revenue but have immaterial bottom-line impact. Eylea biosimilar in retina is an opportunity but PRISM deal is recent. Britt described biosimilars as a steady contributor.

Brian dismissed cash pay as a small subset and emphasized continued growth from new patients becoming clinically appropriate, with payer policies on PA frequency adding variability.

Brian firmly emphasized oncology remains central and untapped, with PRISM timing driven by M&A discipline and seller alignment rather than oncology saturation.

Britt gave a mechanical bridge (~20% H1-to-H2 growth plus ~$100M savings) with the base otherwise flat YoY.

Andrew wouldn't commit to a date ('relatively soon'), describing a wide treatment range across menopause and low-T delivered mainly through owned facilities; Yemi said the investment is embedded in guidance.

Yemi confirmed the sequential softness ex-GLP-1 is mainly the deliberate on-demand sexual-health rotation plus the first quarter without Apostrophe, expected to turn accretive by H2 2026.

Andrew declined to disclose the personalized-transition percentage but detailed the independence wall between the corporate entity and provider groups; partial.

Yemi declined to break out Q4 GLP-1 specifically, reiterating that most revenue is non-GLP-1 and durable, a partial answer that sidestepped the quarter-level figure.

Morici confirmed the VAT is a pass-through to customers with no impact to Align ASPs.

Morici declined the 2027 question and redirected to current-year mix, answering the drivers but not the trajectory.

John attributed Q1 profitability to 2025 restructuring benefits taking hold. Expects productivity and profitability to continue improving with typical quarterly cadence and volume increases. Did not quantify specific Middle East impact in Q2.

Andrew prioritized organic investment, described opportunistic BD (more software assets seen recently), and reaffirmed share buybacks as the primary use of excess capital.

Andrew said gross margins will lead operating margin and cited 20-50bps of comparable Q3 margin gain, but declined to split incremental commercial/R&D/IT/AI investments between Q3 and Q4.

Andrew confirmed the 70bp midpoint raise is entirely volume-driven, no pricing change from initial 4% guide. Volume gains from innovation adoption, diagnostic frequency expansion, and modestly improved clinical visit outlook.